The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study In the Losartan Intervention For End point reduction in hypertension (LIFE) study losartan-compared to atenolol-based antihypertensive treatment showed a tendency towards reducing peripheral revascularization (4.4 vs 57, P ¼ 0.07). This benefit was significant in the patients without peripheral vascular disease or without albuminuria at baseline (both Po0.01), suggesting that losartan may be particularly effective in preventing vascular damage in patients without preexisting vascular damage.
In the Losartan Intervention For End point reduction in hypertension (LIFE) study losartan-compared to atenolol-based antihypertensive treatment showed a tendency towards reducing peripheral revascularization (4.4 vs 57, P ¼ 0.07). This benefit was significant in the patients without peripheral vascular disease or without albuminuria at baseline (both Po0.01), suggesting that losartan may be particularly effective in preventing vascular damage in patients without preexisting vascular damage.
In the LIFE study, the rate of myocardial infarction did not significantly differ between the treatment groups when losartan-compared with atenololbased treatment was administered to patients with hypertension and left ventricular hypertrophy (LVH) for a mean of 4.8 years. 1 On the other hand, in a subgroup of patients in the LIFE study, losartanbased, but not atenolol-based antihypertensive treatment, reduced carotid artery hypertrophy. 2 Furthermore, angiotensin II has experimentally been associated with development of atherosclerosis, 3 and blockage of the renin-angiotensin-aldosterone system may reduce atherosclerosis. 4 In the present analysis, we aimed to identify risk predictors for coronary and peripheral revascularizations in this large study and to investigate the effect of losartanbased compared with atenolol-based antihypertensive treatment on the incidences of coronary and peripheral revascularizations.
The LIFE study design has been previously published. 5 9193 hypertensive patients aged 55-80 years with electrocardiographic (ECG) LVH were randomized to losartan-or atenolol-based antihypertensive treatment for a mean of 4.8 years. The revascularization analyses were pre-specified as part of the LIFE protocol. 5 Coronary revascularization included all coronary artery revascularization procedures (angioplasty, atherectomy and stent) and heart transplant. Peripheral revascularization included all noncoronary artery vascular surgeries and revascularization procedures (aortic aneurysm repair, carotid and peripheral revascularizations and amputations that were the result of arterial vascular insufficiency and diabetes mellitus). Revascularizations were reported by the investigators on endpoint report forms and verified by an independent endpoint classification committee consisting of two cardiology experts. All patients provided written informed consent, and the protocol was approved by all relevant ethical review committees.
Data management and analysis were performed using SPSS 10.1 (SPSS, Chicago, IL, USA) software. Data are presented as mean7s.d. for continuous variables with normal distribution, median and inter-quartile range for continuous variables without normal distribution, and proportions for categorical variables. Only urinary albumin/creatinine ratio (UACR) was distributed non-normally and was transformed using logarithm of 10 to create normal distributions. Unpaired Student's t-test was used to determine differences in continuous variables between groups. Events were analyzed using the intent-to-treat approach. Hazard ratios (HRs) and their 95% confidence intervals (in brackets) for cardiovascular events were assessed using Cox regression analysis adjusting for potential confounders (i.e., age, gender, body mass index, prior cardiovascular disease and treatment allocation). Using backward selection, multivariate models predicting peripheral and coronary revascularization, respectively, were constructed. Two-tailed Po0.05 indicated statistical significance.
Patients undergoing coronary and peripheral revascularization during the study had increased cardiovascular risk factors at baseline, especially the patients in the peripheral revascularization group (Table 1) . Baseline characteristics in the losartan and atenolol groups were comparable in the patients with and without history of angina (Table 2 ) and with and without history of peripheral vascular disease ( Table 3 ). The incidences of coronary revascularization were equal in patients randomized to losartan-versus atenolol-based treatment (both 7.9 per 1000 patient-years, P ¼ NS; Figure 1a) , and there was a trend toward a lower incidence of peripheral revascularization in patients treated with losartan (4.4 vs 5.7 per 1000 patient-years, P ¼ 0.07; Figure 1b) .
In Cox regression analysis, coronary revascularization was predicted by history of angina, diabetes, or myocardial infarction; higher Framingham risk (Table 4b ). The strongest predictors of peripheral revascularization were history of peripheral vascular disease, microalbuminuria and smoking. In patients without peripheral vascular disease, peripheral revascularization was inversely predicted by losartan treatment independently of history of cerebrovascular disease and angina; smoking; higher Framingham risk score, log(UACR), and glucose; and lower body mass index. In patients with peripheral vascular disease, peripheral revascularization was predicted by higher glucose, LVH by Sokolow-Lyon voltage, and serum creatinine. In patients without albuminuria, peripheral revascularization was inversely predicted by losartan treatment independently of history of peripheral vascular disease, myocardial infarction, and cerebrovascular disease; smoking; statin treatment; higher glucose, Framingham risk score, and LVH by Sokolow-Lyon voltage; and lower body mass index. In patients with albuminuria, peripheral revascularization was predicted by history of peripheral vascular disease; higher glucose, LVH by Sokolow-Lyon voltage, and pulse pressure; and lower HDL-cholesterol and body mass index. The beneficial effect of losartan on peripheral revascularization was significant in patients without peripheral vascular disease (Figure 1c , Po0.01) or without microalbuminuria (Figure 1d , Po0.01), but not in patients with peripheral vascular disease or with microalbuminuria, although the two treatment groups had comparable baseline characteristics (Table 1) . Both interactions were statistically significant (Po0.05). Treatment with losartan compared with atenolol showed a trend toward lower incidence of peripheral, but not coronary, revascularization in patients randomized to losartan as compared with atenolol in the LIFE study. Taking cardiovascular risk factors into account, the incidence of peripheral revascularization tended to be significantly lower in patients randomized to losartan. The beneficial effect of losartan on peripheral revascularization was significant in patients without preexisting vascular damage as indicated by the absence of peripheral vascular disease or albuminuria at baseline. This indicates that losartan may be able to prevent, but not reverse, peripheral vascular damage. This is supported by previous findings in a LIFE subpopulation showing that losartan-based antihypertensive treatment prevented progression of peripheral vascular remodeling assessed as minimal forearm vascular resistance, but did not reverse the remodeling. 6 In other words, the development from endothelial dysfunction through subclinical vascular remodeling and atherosclerosis to symptomatic vascular stenosis may at some point become irreversible, supporting the idea of blocking the reninangiotensin-aldosterone system early in time to prevent the development of atherosclerosis. 7 In the Heart Outcomes Prevention Evaluation (HOPE) study, ramipril has been shown to reduce cardiovascular events, including revascularization, in patients with high risk of ischemic heart disease. 8 However, there was a significant lower blood pressure in the ramipril group and the beneficial effect was most pronounced in patients with elevated blood pressure, suggesting that the beneficial effect of ramipril was not independent of the blood pressure reduction. 9 Alternatively, it is possible that patients in LIFE without preexisting vascular damage were especially sensitive to atenolol-induced vasoconstriction demasking subclinical peripheral vascular disease increasing the incidence of peripheral revascularization. However, it is also possible that patients randomized to atenolol were less active, 10 delaying clinical manifestation of peripheral vascular disease decreasing the incidence of peripheral revascularization.
Peripheral revascularization was independently associated with higher Framingham risk score, LVH by Sokolow-Lyon criteria, and hyperglycemia sup- Abbreviations: HDL, high-density lipoprotein; PVD, peripheral vascular disease; UACR, urinary albumin:creatinine ratio. *P o0.05, **Po0.01, ***Po0.001.
